Fulgent Genetics, Inc. (NASDAQ:FLGT) CFO Paul Kim Sells 1,307 Shares

Fulgent Genetics, Inc. (NASDAQ:FLGT) CFO Paul Kim sold 1,307 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $27.25, for a total value of $35,615.75. Following the transaction, the chief financial officer now directly owns 201,897 shares in the company, valued at approximately $5,501,693.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Paul Kim also recently made the following trade(s):

• On Monday, August 28th, Paul Kim sold 10,299 shares of Fulgent Genetics stock. The shares were sold at an average price of $33.62, for a total value of $346,252.38.

Fulgent Genetics Stock Up 2.1 %

FLGT opened at $27.62 on Tuesday. The business has a fifty day moving average of $26.49 and a 200 day moving average of $33.05. Fulgent Genetics, Inc. has a 52-week low of $23.09 and a 52-week high of $44.09. The stock has a market cap of $818.46 million, a P/E ratio of -12.91 and a beta of 1.57.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Friday, November 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.07). Fulgent Genetics had a negative net margin of 22.17% and a negative return on equity of 4.59%. The business had revenue of $84.70 million for the quarter, compared to analysts’ expectations of $64.42 million. During the same quarter in the previous year, the firm earned $0.11 EPS. Fulgent Genetics’s revenue was down 19.9% compared to the same quarter last year. Equities analysts anticipate that Fulgent Genetics, Inc. will post -2.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Fulgent Genetics

A number of large investors have recently bought and sold shares of FLGT. The Manufacturers Life Insurance Company lifted its holdings in shares of Fulgent Genetics by 31.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 10,699 shares of the company’s stock worth $286,000 after buying an additional 2,538 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Fulgent Genetics in the 3rd quarter worth $659,000. Legal & General Group Plc lifted its holdings in shares of Fulgent Genetics by 8.9% in the 3rd quarter. Legal & General Group Plc now owns 113,857 shares of the company’s stock worth $3,045,000 after buying an additional 9,317 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Fulgent Genetics by 37.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 8,589 shares of the company’s stock worth $230,000 after buying an additional 2,335 shares during the period. Finally, Schonfeld Strategic Advisors LLC lifted its holdings in shares of Fulgent Genetics by 55.3% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 21,700 shares of the company’s stock worth $580,000 after buying an additional 7,730 shares during the period. Hedge funds and other institutional investors own 46.09% of the company’s stock.

Analyst Ratings Changes

FLGT has been the topic of several analyst reports. StockNews.com initiated coverage on Fulgent Genetics in a research report on Thursday, October 5th. They set a “hold” rating on the stock. TheStreet downgraded Fulgent Genetics from a “c-” rating to a “d+” rating in a research report on Friday, November 3rd. Finally, Piper Sandler cut their target price on Fulgent Genetics from $37.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, October 16th.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests.